An update on the pharmacotherapeutic strategies for the treatment of dysthymic disorder: a systematic review.

Abstract

INTRODUCTION:

Longer treatment times, more comorbidity, more severe impairments in social, psychological, and emotional functioning, increased healthcare use, and more hospitalizations are all factors that are related to dysthymia. Given the significant prevalence of dysthymia (including persistent depressive disorder) worldwide, its comorbidity with several mental disorders, and the detrimental effects of these comorbidities, it is important to conduct a systematic review to compare the effects of pharmacological acute and maintenance treatments for dysthymia with placebo and standard care in the last 10 years, based on the publication of DSM5.

AREAS COVERED:

This systematic review was performed according to PRISMA guidelines. Databases, including PubMed and Cochrane Central Register of Controlled Trials, were searched to assess the effects of pharmacological acute and maintenance treatments for dysthymia in comparison with placebo and treatment as usual.

EXPERT OPINION:

Our review shows that SSRIs and SNRIs present efficacy for dysthymia treatment, and L-Acetylcarnitine should be investigated further for this condition in elderly patients. The comparison of antidepressant medication versus placebo showed coherent results based on three studies favoring pharmacotherapy as an effective treatment for participants with dysthymia. However, the scarcity of research on continuation and maintenance therapy in people with dysthymia highlights the need for more primary research.

• Authors: Laiana A Quagliato, Diego Primavera, Michele Fornaro, Antonio Preti, Mauro G Carta, Antonio E Nardi
• Journal: Expert opinion on pharmacotherapy (Expert Opin Pharmacother) Pg. 1-6 (Oct 03 2023) ISSN: 1744-7666 [Electronic] England
• PMID: 37787056 (Publication Type: Journal Article, Review)